About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Biomedical Research in Urology group is interested in the study of hormone-dependent cancers, in particular prostate cancer (but not limited to it).
Our efforts are focused on finding, on the one hand, tools that help us in the early diagnosis of the disease, in the best differentiation of tumors according to their aggressiveness and their response to therapy, and finally in finding effective therapies against it.
From a molecular point of view, we focus our studies mainly on cell signaling processes related to the cell cycle and mitosis (with kinesins, kinases and ubiquitin ligases as main targets).
Our multidisciplinary group is made up of molecular biologists and urologists, and we collaborate with oncologists, pathologists and specialists in other diseases when required.
We work with in silico data obtained with different "omics" techniques, samples and clinical data from patients, in vitro and in vivo models, to answer the questions raised.
Once the tumor metastasizes to bone, the metastatic disease become incurable and current therapies are palliative. Thus, to better understand the biology of PC bone metastasis and to investigate new therapeutic options it is crucial to develop new animal models.
We have established new experimental models of PC bone metastasis by inoculation (intratibial and intracardiac) of human PC cell lines in immunodeficient mice to make a suitable model for evaluating novel compounds as future therapeutic approaches. Extensive bone metastases were monitored by in vivo bioluminescence imaging. By applying different strategies we have described new molecular targets involved in the mechanisms of PC bone metastasis.
1) Garcia M, et al. BJU Int. 2014;113:E164-77.
2) Doll A, et al. Arch Esp Urol. 2013;66:463-74.
IP: Joan Morote Robles
Principal Investigator
Anna Santamaría Margalef, PhD
Clinical Associated Researchers
Juan Morote Robles, MD, PhD (co-head Biomedical Research Group in Urology)
Jacques Planas, MD, PhD
PhD Students
Letícia Suárez
Marta Barber
Technician
Adrián García
Past members
Dr. Núria Masiá
Dr. Melissa Bradbury (MD)
Dr. Alfonso Parrilla
Dr. Mireia Oliván
Dr. Blanca Majem
Gabriel Tamayo
BACKGROUND
The efforts of our team are devoted to give answer to the main challenges in the field of cancer (diagnosis, prognosis and therapy), in particular we focus our attention to homone-dependent tumors, namely prostate tumors (but not limited to) and on cell cycle-related signaling pathways, specifically mitosis and the role of key regulatory enzymes (kinesins, kinases and ubiquitin ligases).
RESEARCH STRATEGY AND SCOPE
Alternative therapeutic strategies based on mitotic regulators: kinesins
Alterations in the expression of several mitotic regulators have been associated with tumor formation in many cancers. Recent genomic studies have shown that androgen receptor (AR) activity in hormone-refractory prostate cancer (PCa) is not identical to that displayed in androgen dependent cells. Interestingly, increasing evidence in the last years suggest that castrated-resistance prostate cancer (CRPC) cells have undergone a genetic reprogramming to upregulate the expression of M-phase cell cycle genes. AR selectively and directly upregulates a set of mitotic regulators to promote androgen independent PCa. Enrichment of M-phase proteins and pathways has been found in CRPC chemotherapy-resistant tumors compared with their chemotherapy-naïve counterparts. In this context, the main goal of this research line is to gain novel molecular insights into the progression of PCa, with special emphasis on the involvement of mitotic regulators in the acquisition of prostate tumors androgen independence. Through a proteomic-based approach we have identified drivers of the castration-resistant disease and several mitotic kinesins stand out. We aim at studying their role as potential as therapeutic targets.
Contribution to disfunctionality of mitotic regulators alterations to CIN in certain tumors
We aim at understanding first, the basic molecular mechanisms by which mitotic players (spindle-associated proteins and mitotic kinases such us hBora, Ska, CHICA, Plk1, Aurora A) that normally operate to ensure the error-free segregation of chromosomes, and how are they regulated in time and space and second, and which mechanisms give rise to the chromosomal instability that is typical of tumor cells by taking advantage of the animal and human models of cancer currently used in the laboratory.
BRCA1 and BRCA2-dependent ubiquitination and phosphorylation landscapes in cancer patients
High-grade serous carcinoma (HGSC) is characterized by presenting defects in the homologous recombination repair, most frequently associated to BRCA1 mutations. Although most patients will initially respond to first-line chemotherapy with platinum-based agents, up to a quarter will be resistant to treatment. In recent years we have advanced in the understanding of HGSC tumour physiology and its dependence on BRCA1 and, secondly, have identified protein signature able to discriminate between chemotherapy resistant and sensitive patients. In collaboration with the clinicians at the Gynecology Department at the Vall Hebron Hospital, we have performed a multi-layered proteomic characterization of patient-derived ovarian tissues, which has revealed the importance of both ubiquitination and phosphorylation layers of regulation in modulating key cellular processes in HGSC, their dependency on BRCA1 and the identification of BRCA1 substrates responsible for driving ubiquitination signalling. Also, using discovery and targeted proteomics in HGSC tissues, we have identified a protein signature able to discriminate between chemotherapy resistant and sensitive patients at the time of cancer diagnosis. Collectively, we have performed a comprehensive molecular characterization of HGSC that provides a groundwork for future mechanistic-based studies and the development of new targeted therapies in ovarian cancer. In addition, we advance in the optimization of therapeutic decision making through the identification of a promising protein signature able to predict response to chemotherapy.
On the other hand, previous sequencing studies revealed that alterations of genes associated with DNA damage response (DDR) are enriched in men with mCRPC. Although BRCA2 mutations are known to confer an increased risk of breast and ovarian cancer, recent observations have shown that alterations of BRCA2 are more prevalent than previously appreciated in men with PCa and more frequent than alterations in any other DDR gene. We aim at translating our expertise and results on BRCA1 related to HGSC, to get deeper insights into the functional relevance of BRCA2 mutations in PCa. In close collaboration with the Urology Deparment at Vall Hebron (Dr. Jacques Planas), we also aim at improving the management of patients with BRCA2 mutations.
Drug development
We are interested in testing the therapeutic potential of new synthetic or natural compounds in clinically representative tumor cell lines (of prostate and ovarian cancer) and preclinical mouse models to improve the efficacy and safety of currently available treatments.
ONGOING and PAST COMPETITIVE PROJECTS:
1. 2019PROD00087, SalivOmiX: Prova basada en la detecció de miRNAs en saliva per el diagnòstic precoç del càncer d'ovari AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. Producte. Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/07/2020-31/12/2021. 100.000 €.
2. PI18/01017, SalivOmiX: Test basado en el análisis de miRNAs en saliva para la detección precoz del cáncer de ovario Instituto de Salud Carlos III (FIS). (INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON). 01/2019- 12/2021. 159.720 €. Investigador principal.
3. 2017 SGR 1661, Grup de Recerca Biomèdica en Ginecologia AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. SGR. Anronio Gil Moreno. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/01/2018- 31/12/2020. 33.000 €. Miembro de equipo.
4. AECC/2017/SANTAMARIA, Nuevos enfoques terapéuticos para el cáncer de próstata hormono-refractario basados en la kinesina KIF11 Asociación Española Contra el Cáncer. AECC - Junta Barcelona (Conveni ajudes per a la investigació 2017). Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2018-2019. 34.700 €. Investigador principal.
5. 2016 LLAV 00056, Salivomics: identification of genòmic markers to improve early ovarian càncer detection AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. Llavor. Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2017-2018. 20.000 €. Investigador principal.
6. PI15/02238, Sensibilidad a quimioterapia en cáncer de ovario: Plk1 y Aurora A quinasas como terapia alternativa que permitan mejorar la respuesta antitumoral y la estratificación de pacientes FIS. Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2016-2018. 122.815 €. Investigador principal.
7. RTC-2015-3821-1, Desarrollo de nuevas aproximaciones en el manejo individualizado de pacientes con cáncer ginecológico (PredicareGYN) Ministerio de Economía y Competitividad. RETOS. Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2015-2018. 348,6 €. Co-Investigador principal.
8. Transcripció, traducció i mitosi en càncer de pròstata resistent a teràpia.TRAMIT-CAP (GRE) AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. Grup de Recerca Emergent (SGR-AGAUR). Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/01/2014-31/12/2016. 16.000 €. Co-Investigador principal.
9. CP13/00158, Characterization of Plk1 alterations and consequences in the progression tumorigenesis, with a focus in prostate cancer Miguel Servet (FIS). Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2014-2016. 120.500 €. Investigador principal.
10. Control of chromosome segregation fidelity Swiss Cancer League. Anna Santamaria Margalef. (Biozentrum - University of Basel). 02/2011-02/2014. 160.000 €. Investigador principal.
ACTIVE COLLABORATIONS WITH BIOTECH COMPANIES:
Atrys (Madrid, Spain)
Oncostellae (Santiago de Compostela, Spain)
4SC (Münich, Germany)
SELECTED PUBLICATIONS (last 5 years)
Currently under review:
- Bradbury M; … Gil-Moreno A; Sabidó E*; Santamaria, A*. BRCA1 mutations reshape the signaling landscape in high-grade serous ovarian cancer patients. Science Signalling (under review) (*equal contribution).
- Bradbury M; … Gil-Moreno A; Santamaria, A*; Sabidó E*. Molecular advances for the management of high-grade serous ovarian cancer patients. Cancers (under review) (*equal contribution).
1.- Alfonso Parrilla; Marta Barber; Blanca Majem; et al.,; Miguel F Segura; Antonio Gil Moreno; Anna Santamaria. Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer. Cancers (Basel). 12 - 4, pp. pii:E886. 06/04/2020. DOI: 10.3390/cancers12040886.
2.- Blanca Majem; Alfonso Parrilla; et al.,; Antonio Gil Moreno; Miguel F Segura; Anna Santamaría. MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. Oncogene. 38 - 32, pp. 6035 - 6050. 08/2019. ISSN 1476-5594 DOI: 10.1038/s41388-019-0860-0
3.- Soriano A; Masanas M; Boloix A; et al; Santamaria A; Segura MF. 2019. Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as a new tumour-suppressive microRNAs in neuroblastoma. Cell Mol Life Sci. 76-11, pp.2231-2243. ISSN 2041-1723.
4.- Óscar Rapado-González, Blanca Majem, et al., Anna Santamaría, Rafael López-López, Laura Muinelo-Romay, María Mercedes Suarez-Cunqueiro. A Novel Saliva-Based miRNA Signature for Colorectal Cancer Diagnosis. J. Clin. Med. 2019, 8, 2029;doi:10.3390/jcm8122029
5.- Óscar Rapado-González, Blanca Majem, Laura Muinelo-Romay, Ana Álvarez-Castro, Anna Santamaría , Antonio Gil-Moreno , Rafael López-López , María Mercedes Suárez-Cunqueiro. Human salivary microRNAs in Cancer. J Cancer. 2018 Jan 6;9(4):638-649. doi: 10.7150/jca.21180. eCollection 2018.
6.-Devis, L; Moiola, C; Masia, N; et al; Santamaria, A; Colas, E. 2017. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion and metastasis in early stage endometrioid endometrial cáncer. Journal of Pathology. WILEY-BLACKWELL. 241-4, pp.475-487. ISSN 0022-3417.
7.- A Almazán-Moga, P Zarzosa, C Molist, P Velasco , J Pyczek, K Simon-Keller, I Giralt, I Vidal, N Navarro, M F Segura, A Soriano, S Navarro, O M Tirado, J C Ferreres, A Santamaria, R Rota, H Hahn, J Sánchez de Toledo , J Roma, S Gallego. 2017. Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands. Br J Cancer. 117-9, pp.1314-1325. ISSN 0007-0920. 1
8.- Redli, PM; Gasic, I; Meraldi, P; Nigg, EA; Santamaria, A. The Ska complex promotes Aurora B activity to ensure chromosome biorientation. Journal of Cell Biology. 215 - 1, pp. 77 – 93, 2016. ROCKEFELLER UNIV PRESS, 10/10/2016. ISSN 0021-9525DOI: 10.1083/jcb.201603019
9.- Thomas, Y.; Cirillo, L.; Panbianco, C.; et al; Santamaria, A.; Gotta, M. 2016. Cdk1 Phosphorylates SPAT-1/Bora to Promote Plk1 Activation in C. elegans and Human Cells. Cell Reports. CELL PRESS. 15-3, pp.510-518. ISSN 2211-1247.
10.- Abad, MA; Zou, J; Medina-Pritchard, B; Nigg, EA; Rappsilber, J; Santamaria, A; Jeyaprakash, AA. 2016. Ska3 Ensures Timely Mitotic Progressionby Interacting Directly With Microtubules and Ska1 Microtubule Binding Domain. Scientific Reports. NATURE PUBLISHING GROUP. 6, pp.34042. ISSN 2045-2322.
11.- Maria-Alba* Abad; Medina, B*; Santamaria, A*; Zou, J; Plasberg-Hill, C; Madhumalar, A; Jayachandran, U; Rappsilber, J; Nigg, EA; Jeyaprakash, AA. Structural Basis for the Microtubule-Recognition by the human kinetochore Ska complex. Nature Communications. 5, pp. 2964. NATURE PUBLISHING GROUP, 2015. ISSN 2041-1723 (*equal contribution)
IP: Anna Santamaria Margalef
Prostate cancer (PC) is the second leading cause of death for cancer in men of the western Countries. While considerable advances have been made in the treatment of localized, organ-confined tumors, metastatic PC is virtually incurable and most deaths from this disease are due to the high resistance of metastasis to conventional therapies (androgen-depletion-therapy, ADT). Therefore, more precise markers for the detection of the incipient resistant tumor and more effective targets that eliminate the resistant clones are needed.
A principal aim is to identify relevant molecular pathways specifically active in aggressive prostate cancer, useful for an early detection of ADT resistant tumors and for treatment strategies.
In our studies, we have discovered the human Prostate Tumor OVerexpressed-1 (PTOV1) gene, later called Acid-2, and a second gene with a PTOV module, PTOV2, later called MED25, a component of Mediator (1-2).
The detection of PTOV1 in high-grade PIN (HGPIN) premalignant lesions is helpful to identify patients with higher probability to develop PC (3). PTOV1 ectopic expression promotes proliferation, invasion and metastasis of ADT resistant cells (1,2,4,5). PTOV1 induces the epithelial-mesenchymal-transition (EMT) and increased metastasis of PC3 cells (4). Mechanistically, PTOV1 is implicated in multiple processes controlling cell fate: it promotes mRNA translation leading to a specific increased synthesis of c-Jun and Snai1 oncogenes (4), and it is a transcriptional repressor of HES1 and HEY1 genes, leading to inhibition of Notch signalling in metastatic PC (5). PTOV1 significantly affect the self-renewal potential of the cancer stem cell populations of PC3 cells (5).
Current objectives of our line of research are: (i) Determine the role of PTOV1 in the resistance to ADT and chemotherapy (taxols). (ii) Characterize the sub-clonal cancer stem cell populations (CSC) present in metastatic primary tumors and the genes and factors responsible for the development of the resistance to ADT.
1) Benedit P, et al. Oncogene 2001;20:1455–1464.
2) Santamaria A, et al. Am J Pathol 2003;162:897–905.
3) Morote J, et al. Clin Cancer Res 2008:14:2617-2622.
4) Marqués N, et al. Oncogene 2014;33(9):1124-34.
5) Alaña L et al., Mol Cancer 2014;13:74.
IP: Cell signaling and cancer progression
One main focus of our research is the discovery of new biomarkers for the early detection of prostate cancer (PC). The detection of proteins, RNA or miRNAs from easily accessible body fluids, such as blood or urine, will make possible to diagnose the disease at an early/pre-symptomatic stage, or monitoring responses to therapy in a simple and non-invasive way. This will improve the specificity of the currently used PSA serum measurements.
We have identified a three-gene panel in urine able to increase the PSA specificity for the detection of PC, and using liquid chromatography, mass spectrometry and triple quadruple mass spectrometry (LC/MSMS, SRM), we have discovered the presence of specific, differential proteomic profiles in the urine of PC patients.
Furthermore, we have identified a genomic profile able to detect PC in patients previously diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN). Such profile should have an application in the clinics and improve decision making in the diagnosis and treatment of PC (Figure).
1) Sequeiros T, et al. Prostate 2015; Accepted;
2) Rigau M*, Olivan M*, et al. Int. J. Mol. Sci. 2013;14: 12620-12649;
3) Rigau M, et al. Prostate 2011; 71:1736-45;
4) Rigau M et al. Prostate 2010; 70:1760-7
IP: Olga Méndez Fernández Collaborators: Berta Miró Cau, Marc Simo Perdigo, David Ruiz Casajuana, Jacques Planas Morin, Richard Mast Funding agency: Instituto de Salud Carlos III Funding: 127500 Reference: PI23/01310 Duration: 01/01/2024 - 31/12/2026
IP: Oriol Bestard Matamoros Collaborators: Ana Pérez González, Francesc Bosch Albareda, Francesc Moreso Mateos, Enric Trilla Herrera, Joana Sellarés Roig, Irina Betsabe Torres Rodriguez, Enric Miret Alomar, Manel Perelló Carrascosa, Nestor Gabriel Toapanta Gaibor, Maria Antonia Emilia Meneghini, Delphine Kervella, Elena Isabel Crespo Gimeno Funding agency: Fundación Invest. Médica Mutua Madrileña Funding: 109725 Reference: FMM/ORIOL_BESTARD Duration: 15/09/2023 - 14/09/2025
IP: Enric Trilla Herrera Collaborators: - Funding agency: Asociación Española de Urología Funding: 25000 Reference: FIU2022/TRILLA Duration: 29/07/2023 - 28/07/2025
IP: Olga Méndez Fernández Collaborators: Berta Miró Cau, FLUTE: Federate Learning and mUlti-party computation Techniques for prostatE cancer, Enric Trilla Herrera Funding agency: EUROPEAN COMMISSION Funding: 490375 Reference: FLUTE_HE-HLTH22 Duration: 01/05/2023 - 30/04/2026
PMID: 37025471 Journal: BJUI compass Year: 2023 Reference: BJUI Compass. 2022 Dec 28;4(3):266-268. doi: 10.1002/bco2.211. eCollection 2023 May. Impact factor: Publication type: Paper in international publication Authors: Abascal, Jose M; Campistol, Miriam; Morote, Juan; Servian, Pol; Trilla, Enrique; Triquell, Marina et al. DOI: 10.1002/bco2.211
PMID: 37231687 Journal: European Stroke Journal Year: 2023 Reference: Eur Stroke J. 2023 Jun;8(2):557-565. doi: 10.1177/23969873231156260. Epub 2023 Mar 2. Impact factor: Publication type: Paper in international publication Authors: Abilleira, Sonia; Almendros, Mari Cruz; Canovas, David; Carrion, Dolors; Catena, Esther; Cocho, Dolores; Colom, Carla; Costa, Xavier; Deulofeu, Anna; Diaz, Gloria et al. DOI: 10.1177/23969873231156260
PMID: 37244767 Journal: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS Year: 2023 Reference: Urol Oncol. 2023 May 25:S1078-1439(23)00161-8. doi: 10.1016/j.urolonc.2023.05.003. Impact factor: Publication type: Paper in international publication Authors: Abascal, Jose M; Asiain, Ignacio; Celma, Anna; de Manuel, Gemma Garcia; Morote, Juan; Munoz-Rivero, Marta V; Munoz-Rodriguez, Jesus; Paesano, Nahuel; Picola, Natalia; Ruiz-Plazas, Xavier et al. DOI: 10.1016/j.urolonc.2023.05.003
PMID: 37331529 Journal: HUMAN PATHOLOGY Year: 2023 Reference: Hum Pathol. 2023 Jun 16:S0046-8177(23)00135-1. doi: 10.1016/j.humpath.2023.06.002. Impact factor: Publication type: Paper in international publication Authors: Acosta, Andres M; Akgul, Mahmut; Alvarado-Cabrero, Isabel; Aron, Manju; Celada, Manuel Manrique; Cheng, Liang; Chou, Angela; Collins, Katrina; Contreras, Felix; de Torres, Ines et al. DOI: 10.1016/j.humpath.2023.06.002
PMID: 34602313 Journal: EUROPEAN UROLOGY Year: 2022 Reference: Eur Urol. 2022 Jan;81(1):124-125. doi: 10.1016/j.eururo.2021.09.019. Epub 2021 Sep 30. Impact factor: 20.096 Publication type: Letter whit IF Authors: Morote, Juan; Diaz, Fernando; Celma, Anna; Planas, Jacques; Trilla, Enrique et al. DOI: 10.1016/j.eururo.2021.09.019
PMID: 34983087 Journal: World Journal of Mens Health Year: 2022 Reference: World J Mens Health. 2022 Jan;40(1):74-86. doi: 10.5534/wjmh.210061. Impact factor: 5.4 Publication type: Review in international publication Authors: Casado, Enrique; Borque-Fernando, Angel; Caamano, Manuel; Grana, Jenaro; Munoz-Rodriguez, Jesus; Morote, Juan et al. DOI: 10.5534/wjmh.210061
PMID: 34352790 Journal: UROLOGIA INTERNATIONALIS Year: 2022 Reference: Urol Int. 2022;106(2):154-162. doi: 10.1159/000517543. Epub 2021 Aug 5. Impact factor: 2.089 Publication type: Paper in international publication Authors: Raventos Busquets, Carles X; Semidey, M Eugenia; Lozano Palacio, Fernando; Carrion Puig, Albert; Aula Olivar, Ana; De Torres Ramirez, Ines M; Trilla Herrera, Enrique et al. DOI: 10.1159/000517543
PMID: 35767122 Journal: Insights into Imaging Year: 2022 Reference: Insights Imaging. 2022 Jun 29;13(1):109. doi: 10.1186/s13244-022-01251-2. Impact factor: 5.231 Publication type: Paper in international publication Authors: Escobar, Manuel; Tomasello, Alejandro; Perez Lafuente, Mercedes; Andreu, Jordi; Grinon, Jesus; Sanchez-Tirado, Cristina; Mast, Richard; Antolin, Andreu; Roson, Nuria et al. DOI: 10.1186/s13244-022-01251-2
PMID: 34944822 Journal: Cancers Year: 2021 Reference: Cancers (Basel). 2021 Dec 9;13(24). pii: cancers13246202. doi: 10.3390/cancers13246202. Impact factor: 6.639 Publication type: Paper in international publication Authors: Santamaria, Anna, Rodriguez-Barrueco, Ruth, Morote, Juan, de la Cruz, Xavier, Olivan, Mireia, Garcia, Marta, Suarez, Leticia, Guiu, Marc, Gros, Laura, Mendez, Olga et al. DOI: 10.3390/cancers13246202
PMID: 33607371 Journal: EUROPEAN JOURNAL OF RADIOLOGY Year: 2021 Reference: Eur J Radiol. 2021 Apr;137:109589. doi: 10.1016/j.ejrad.2021.109589. Epub 2021 Feb 12. Impact factor: 3.528 Publication type: Paper in international publication Authors: Salazar, Aina, Planas, Jacques, Celma, Ana, Cuadras, Merce, Roche, Sarai, Mast, Richard, Morote, Juan, Trilla, Enrique, Regis, Lucas et al. DOI: 10.1016/j.ejrad.2021.109589
PMID: 33194736 Journal: Frontiers in Oncology Year: 2020 Reference: Front Oncol. 2020 Oct 22;10:586069. doi: 10.3389/fonc.2020.586069. eCollection 2020. Impact factor: 4.848 Publication type: Review in international publication Authors: Kondoh, Hiroshi, Alvarez-Meythaler, Jose G, Garcia-Mayea, Yoelsis, Mir, Cristina, LLeonart, Matilde E et al. DOI: 10.3389/fonc.2020.586069
PMID: 32647375 Journal: Communications Biology Year: 2020 Reference: Commun Biol. 2020 Jul 9;3(1):366. doi: 10.1038/s42003-020-1092-0. Impact factor: 4.165 Publication type: Paper in international publication Authors: Granado-Martinez, Paula, Garcia-Ortega, Sara, Gonzalez-Sanchez, Elena, McGrail, Kimberley, Selgas, Rafael, Grueso, Judit, Gil, Rosa, Naldaiz-Gastesi, Neia, Rhodes, Ana C, Hernandez-Losa, Javier et al. DOI: 10.1038/s42003-020-1092-0
PMID: 31779212 Journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Year: 2019 Reference: Int J Mol Sci. 2019 Nov 26;20(23):5950. doi: 10.3390/ijms20235950. Impact factor: Publication type: Paper in international publication Authors: Cortes, Javier; Mendez, Olga; Perez, Jose; Racca, Fabricio; Soberino, Jesus; Villanueva, Josep et al. DOI: 10.3390/ijms20235950
PMID: 31757017 Journal: Journal of Clinical Medicine Year: 2019 Reference: J Clin Med. 2019 Nov 20;8(12). pii: jcm8122029. doi: 10.3390/jcm8122029. Impact factor: 5.688 Publication type: Paper in international publication Authors: Rapado-Gonzalez, Oscar, Majem, Blanca, Alvarez-Castro, Ana, Diaz-Pena, Roberto, Abalo, Alicia, Suarez-Cabrera, Leticia, Gil-Moreno, Antonio, Santamaria, Anna, Lopez-Lopez, Rafael, Suarez-Cunqueiro, Maria Mercedes et al. DOI: 10.3390/jcm8122029
PMID: 31278368 Journal: ONCOGENE Year: 2019 Reference: Oncogene. 2019 Aug;38(32):6035-6050. doi: 10.1038/s41388-019-0860-0. Epub 2019 Jul 5. Impact factor: 6.634 Publication type: Paper in international publication Authors: Majem, Blanca, Parrilla, Alfonso, Jimenez, Carlos, Suarez-Cabrera, Leticia, Barber, Marta, Marin, Andrea, Castellvi, Josep, Tamayo, Gabriel, Moreno-Bueno, Gema, Ponce, Jordi et al. DOI: 10.1038/s41388-019-0860-0
PMID: 25418557 Journal: Proteomics Clinical Applications Year: 2015 Reference: Proteomics Clin Appl. 2015 Apr;9(3-4):348-57. doi: 10.1002/prca.201400131. Epub 2015 Feb 10. Impact factor: Publication type: Paper in international publication Authors: Mendez, Olga; Villanueva, Josep et al. DOI: 10.1002/prca.201400131
PMID: 23268930 Journal: MOLECULAR & CELLULAR PROTEOMICS Year: 2013 Reference: Mol Cell Proteomics. 2013 May;12(5):1046-60. doi: 10.1074/mcp.M112.021618. Epub 2012 Dec 26. Impact factor: Publication type: Paper in international publication Authors: Baselga, Jose; Gregori, Josep; Mendez, Olga; Salvans, Candida; Villanueva, Josep; Villarreal, Laura et al. DOI: 10.1074/mcp.M112.021618
PhD student: Marta Barber Servera Director/s: Anna Santamaria Margalef University: Universitat Autònoma de Barcelona Year: 2023
PhD student: Aina Salazar Gabarro Director/s: Joan Morote Robles, Lucas Regis Plácido University: Universitat Autònoma de Barcelona Year: 2022
PhD student: Carlos Gasanz Serrano Director/s: Joan Morote Robles, Carles Xavier Raventós Busquets University: Universidad Autònoma de Barcelona Year: 2018
PhD student: Verónica Cánovas Hernández Director/s: Rosanna Paciucci Barzanti University: Universidad Autònoma de Barcelona Year: 2017
PhD student: Ana Celma Domènech Director/s: Jaume Reventós Puigjaner, Joan Morote Robles University: Universidad Autònoma de Barcelona Year: 2009
On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.
The work led by Dr. Regis demonstrates that performing robotic reconstruction after radical prostatectomy is associated with better urinary control.
A clinical trial with the prototype of the device shows that the use of this technology improves patient monitoring by nurses and reduces post-surgical complications.
